GE Healthcare grants license for biomagnetic isolation of nucleic acids to NorDiag ASA
GE Healthcare, a unit of General Elecrtic, announced that it has completed a license agreement with NorDiag ASA, granting NorDiag ASA access to GE Healthcare patents for the biomagnetic isolation of nucleic acids. The license, which is valid for the lifetime of the patents, grants NorDiag ASA certain rights with respect to the isolation and purification of nucleic acids using GE Healthcare's proprietary magnetic separation technology.
According to the company, GE Healthcare's patented methods for magnetic separation offer significant advantages over conventional techniques for the isolation and purification of biomolecules such as DNA and RNA from laboratory and clinical samples. In particular, the proprietary protocols will allow diagnosis from smaller-volume patient samples because they increase the yield of nucleic acid from disease-causing pathogens isolated from patient samples.
"This license recognizes the considerable value that our biomagnetic isolation technology can bring to the diagnosis of infectious diseases," said Eric Roman, General Manager, Genomic Sciences, GE Healthcare. "We are pleased to grant NorDiag ASA access to our patents in this area, which will allow them to commercialise products that can isolate nucleic acids from difficult clinical samples."
Financial terms were not disclosed.
Other news from the department business & finance
